Open Access Full Text Article

RETRACTION

LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p [Retraction]

Han X, Liu J, Liu Y, Mou L, Li C. Cancer Manag Res. 2021;13:4393-4401.

We, the Editors and Publisher of Cancer Management and Research, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figure 3 with images from other unrelated articles. Specifically,

Images for Figure 3E and 3F have been duplicated with images in Figures 4A and 4B from Xu L, Ni N, Gao H, Hu P. MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients. *Oncology Letters*. 2021;21:327. <u>https://doi.org/10.3892/ol.2021.12589</u>; Figure 4B from Wang C, Wang J, Zhang J, et al. MicroRNA-623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer. *Oncology Letters*. 2020;20:386. <u>https://doi.org/10.3892/ol.2020.12249</u>; and Figure 4B from Lu Y, Zhang X, Zhang H, Zhu Z. Prognosis and Biological Function of miR-3195 in Non-Small Cell Lung Cancer. *Cancer Manag Res*. 2022;14:169-176. <u>https://doi.org/10.2147/CMAR.S345618</u>.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as 'Retracted'.

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

https://doi.org/10.2147/CMAR.S448606

Received: 7 November 2023 Accepted: 7 November 2023 Published: 10 November 2023 Cancer Management and Research 2023:15 1267

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).